共 99 条
[1]
Henriksen OM(2017)Brain Tumor Registry of Japan (2005–2008) Neurol Med Chir (Tokyo) 57 9-102
[2]
Del Mar Álvarez-Torres M(2022)High-Grade Glioma Treatment Response monitoring biomarkers: a position Statement on the evidence supporting the Use of Advanced MRI techniques in the Clinic, and the latest bench-to-Bedside developments. Part 1: perfusion and diffusion techniques Front Oncol 12 810263-202
[3]
Figueiredo P(2020)VEGF levels in patients with glioma: a systematic review and meta-analysis Rev Neurosci 32 191-1003
[4]
Seyedmirzaei H(2005)MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997-800
[5]
Shobeiri P(2015)Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Neuro Oncol 17 784-573
[6]
Turgut M(2017)Evaluation of recurrent high-grade gliomas treated with bevacizumab: a preliminary report of 3D pseudocontinuous artery spin labeling Magn Reson Imaging 46 565-1972
[7]
Hegi ME(2010)Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 1963-1156
[8]
Diserens AC(2015)Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial Neuro Oncol 17 1148-1147
[9]
Gorlia T(2015)Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma Neuro Oncol 17 1139-193
[10]
Hutterer M(2019)Comparisons between PET with 11 C-Methyl-L-Methionine and arterial spin labeling perfusion imaging in recurrent glioblastomas treated with Bevacizumab Clin Nucl Med 44 186-27